Indiana Primary Health Care Association competitors

As chief executive officer of Magellan Rx Management, Mostafa Kamal is responsible for all of Magellan’s pharmacy business lines, including the commercial, government and specialty pharmacy divisions. He leads the strategy, operations, growth and profitability of Magellan Rx Management with the overarching goal of delivering innovative, best-in-class drug management solutions to help clients improve the health of the people they serve, as well as the overall quality and cost of care. Previously, Kamal was senior vice president and general manager of Magellan Rx Management’s specialty pharmacy business. In this role, he led sales, account management, operations and product development across the division, delivering industry-leading strategies and solutions to help clients successfully manage complex specialty pharmaceuticals in one of the fastest growing areas of healthcare spending. As chief underwriting officer, he directed the organization’s overall pricing and risk management strategies, and served as vice president of pricing, underwriting and analytics, where he developed financial strategies to help clients manage their pharmacy spend. Before joining Magellan, Kamal held various roles with Medco Health Solutions, Inc., with responsibility for pricing, underwriting, strategy and Medicare Part D products and services. Additionally, he worked with clients to develop strategies to address healthcare reform and associated product offerings to ensure clients were successfully positioned in the post-healthcare reform era. Kamal received his bachelor’s degree in economics from Rutgers University.

Christopher D. Hillyer, MD, President and CEO and Chief Scientific Officer of New York Blood Center (NYBC), and Professor, Department of Medicine, Weill Cornell Medical College, was previously the endowed Distinguished Service Professor, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, where he served as director of the Emory Center for Transfusion and Cellular Therapies. He is board certified in transfusion medicine, hematology, medical oncology and internal medicine. He is an editor of 12 textbooks including the 16-18th editions of the AABB Technical Manual, and is recognized internationally as an expert in hematology, blood transfusion, and cellular therapies. His book, Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects, has become a primary resource throughout the world. Dr. Hillyer has authored more than 175 articles pertaining to transfusion, stem cells, erythropoiesis, and virology, and has been awarded millions of dollars in research funding from the National Institutes of Health, the CDC, and other agencies. He is a past-president of AABB, a former trustee of the National Blood Foundation, and served as an associate editor of TRANSFUSION.He is the 2014 Emily Cooley Award recipient for his “significant commitment and contributions to the field of transfusion medicine..." and was recognized with two Tiffany Awards from the American Red Cross for his work in Africa. Dr. Hillyer is an architect of NYBC Ventures, co-founder of Transfusion & Transplantation Technologies, Inc. (3Ti), HemeXcel Purchasing Alliance, and HemeXcel Resources, and holds a number of patents related to blood banking and cellular therapies. He has served on a number of for-profit and not-for-profit boards.Dr. Hillyer received his BS from Trinity College with Honors and his MD from the University of Rochester School of Medicine, with postgraduate fellowships in hematology-oncology, transfusion medicine and bone marrow transplantation at Tufts-New England Medical Center in Boston.